Can Cannabidiol (CBD) Cure Schizophrenia? GW Pharmaceuticals Says Yes!


For some, every new week starts with a modicum of hope. For me, that hope is that marijuana’s active ingredients will soon be recognized by the medical community as a groundbreaking medicine…and this past Monday, that aspiration got a little bit higher. After receiving lofty praise for their cannabinoid-based medicine aimed at treating pediatric epilepsy, cancer pain, and type II diabetes – GW pharmaceuticals announced on Monday they’ve begun their phase II clinical trial of a cannabinoid-based medicine meant to treat schizophrenia.

GW pharmaceuticals has a long and proven track record when it comes to medical marijuana, and have already successfully demonstrated the massive potential of the plant’s cannabinoids with Sativex; a spray that helps offset oncological pain. Not satisfied with their success, GWPH then took on epilepsy by developing Epidiolex. A cannabinoid-based drug that has the potential to be nothing short of a revolutionary treatment for those kids stricken with epilepsy. Now, the company is taking on schizophrenia with a purified CBD extract…and the early findings are extremely encouraging. The phase II clinical trials are showing the cannabinoids innate ability to mitigate schizophrenic symptoms – while at the same time reducing the side effects of other currently utilized antipsychotics.

While some claim smoking pot can cause a temporary psychosis like effect, the CBD cannabinoid is not the offender, but rather it’s THC that’s the culprit. THC is the psychoactive cannabinoid responsible for getting people “high.” Conversely, study after study suggest that marijuana’s CBD cannabinoid has the exact opposite effect.

Even the federal government’s website, “PubMed” reported that; “Clinical and neurobiological findings suggest that the cannabinoids and the endocannabinoid system may be implicated in the pathophysiology and treatment of schizophrenia. Our results reinforce the role of the endocannabinoid system in the sensorimotor gating impairment related to schizophrenia, and point to cannabinoid drugs as potential therapeutic strategies.”

Now, all GW has to accomplish is to prove the compounds effectiveness during its phase II trial, which will enlist 80 patients to research the new cannabis-based drug, temporarily known as GWP42003. Results are expected by the second half of 2015.



About Author

Born in Long Beach, raised on the central coast: I surf, dab, burn, and blog – though not necessarily in that order. I'm a husband, a father and a lifelong consumer of connoisseur grade weed. I don't drink alcohol or consume any other "drugs." I consider myself to be living proof that weed is not a gateway drug. If it were, I'd be in some serious trouble. Instead, as a 50-year-old ex-realtor that has been smoking weed for nearly 80% of my life (just did the math) ... I can only say, marijuana is safer than prescription pills or alcohol could ever hope to be for calming what stirs the savage beast.


Leave A Reply